rs1555206402
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
rs763059810
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Multivariate logistic regression analysis with adjustment for age, body mass index, and the prevalence of smoking, diabetes mellitus, hypercholesterolemia, and hyperuricemia revealed that 2 polymorphisms (825C-->T in the G protein beta3 subunit gene and 190G-->A in the CC chemokine receptor 2 gene) were significantly associated with hypertension in men and that one polymorphism (-238G-->A in the tumor necrosis factor alpha gene) was significantly associated with hypertension in women.
|
12654703 |
2003 |
rs76863441
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Multivariate logistic regression analysis with adjustment for age, body mass index, and the prevalence of smoking, hypertension, diabetes mellitus, and hyperuricemia revealed that three polymorphisms [994G --> T (Val279Phe) in the platelet-activating factor acetylhydrolase gene, 242C --> T (His72Tyr) in the NADH/NADPH oxidase p22 phox gene, and 1100C --> T in the apolipoprotein C-III gene] were significantly associated with CAD in men with hypercholesterolemia.
|
14709372 |
2004 |
rs5443
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Despite the sufficient statistical power, this study could not demonstrate the significant influence of C825T on hyperuricemia or serum uric acid.
|
16707857 |
2006 |
rs1217691063
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Results from this study suggest that mutation of 5-MTHFR C677T contributes to the higher uric acid levels in both males and females and may be a risk factor for hyperuricemia.
|
17010581 |
2007 |
rs4994
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Trp64Arg polymorphism of the beta-3 adrenergic receptor may be independently associated with hyperuricemia in males.
|
17225053 |
2007 |
rs6837293
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In SNP genotyping analysis at the neighbourhood regions of marker D4S3243 for the case-control subjects, the polymorphisms rs7688672 and rs6837293, located on the cGMP-dependent protein kinase II (cGK II) gene, were found to relate significantly to gout disease in a recessive model after adjustment of hyperuricaemia (OR = 2.89, 95% CI 1.19 to 7.02 and OR = 2.72, 95% CI 1.13 to 6.54, respectively).
|
18678579 |
2009 |
rs7688672
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In SNP genotyping analysis at the neighbourhood regions of marker D4S3243 for the case-control subjects, the polymorphisms rs7688672 and rs6837293, located on the cGMP-dependent protein kinase II (cGK II) gene, were found to relate significantly to gout disease in a recessive model after adjustment of hyperuricaemia (OR = 2.89, 95% CI 1.19 to 7.02 and OR = 2.72, 95% CI 1.13 to 6.54, respectively).
|
18678579 |
2009 |
rs893006
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The rs893006 polymorphism in SLC22CA12 was confirmed to be a genetic risk for hyperuricaemia among the Chinese male population.
|
19306160 |
2009 |
rs7932775
|
|
|
0.010 |
GeneticVariation |
BEFREE |
These SNPs had a joint additive effect of risk of HUA, with those individuals carrying at least one 'A' allele at the intron 3 SNP and two 'C' alleles at rs7932775 having a 5.88-fold (95% CI 1.25 to 15.57) increased risk of HUA in comparison to those with no risk alleles.
|
19833602 |
2010 |
rs1137070
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We also found that MAOA enzyme activity by rs1137070 allele was associated with hyperuricemia and gout (P for trend = 1.53 x 10(-6) vs. wild-type allele).
|
19915868 |
2010 |
rs1217691063
|
|
|
0.030 |
GeneticVariation |
BEFREE |
We hypothesized that hyperuricemia would be associated with methylenetetrahydrofolate reductase (MTHFR) C677T and thymidylate synthase (TS) 28-bp tandem repeat polymorphism.
|
19917450 |
2009 |
rs4994
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Trp64Arg polymorphism of the ADRB3 gene predicted the risk of developing hyperuricemia in this adult population.
|
20008926 |
2010 |
rs2231142
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Associations of the rs2231142 variant with serum uric acid levels and prevalence of gout and hyperuricaemia were examined.
|
20421215 |
2010 |
rs6855911
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The polymorphism rs6855911 in SLC2A9 may be a genetic marker to assess risk of hyperuricemia among Chinese male Han population.
|
20972595 |
2011 |
rs4994
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The common polymorphism rs4994 [c. T387C, p. Trp64Arg (W64R)] of the lipolysis regulator beta-3-adrenergic receptor (ADRB3) was identified as a marker in the pathogenesis of hyperuricemia.
|
21285172 |
2011 |
rs1025993235
|
|
|
0.010 |
GeneticVariation |
BEFREE |
ZPBP2 p.T69I was at the non-conserved region and was predicted to be benign by in silico analysis, whereas GPATCH8 p.A979P was at a highly conserved region and was predicted to be deleterious, which made p.A979P a conceivable candidate for juvenile-onset hyperuricemia.
|
21594610 |
2011 |
rs1209613132
|
|
|
0.010 |
GeneticVariation |
BEFREE |
ZPBP2 p.T69I was at the non-conserved region and was predicted to be benign by in silico analysis, whereas GPATCH8 p.A979P was at a highly conserved region and was predicted to be deleterious, which made p.A979P a conceivable candidate for juvenile-onset hyperuricemia.
|
21594610 |
2011 |
rs1230053514
|
|
|
0.010 |
GeneticVariation |
BEFREE |
ZPBP2 p.T69I was at the non-conserved region and was predicted to be benign by in silico analysis, whereas GPATCH8 p.A979P was at a highly conserved region and was predicted to be deleterious, which made p.A979P a conceivable candidate for juvenile-onset hyperuricemia.
|
21594610 |
2011 |
rs189660050
|
|
|
0.010 |
GeneticVariation |
BEFREE |
ZPBP2 p.T69I was at the non-conserved region and was predicted to be benign by in silico analysis, whereas GPATCH8 p.A979P was at a highly conserved region and was predicted to be deleterious, which made p.A979P a conceivable candidate for juvenile-onset hyperuricemia.
|
21594610 |
2011 |
rs727502862
|
|
|
0.010 |
GeneticVariation |
BEFREE |
ZPBP2 p.T69I was at the non-conserved region and was predicted to be benign by in silico analysis, whereas GPATCH8 p.A979P was at a highly conserved region and was predicted to be deleterious, which made p.A979P a conceivable candidate for juvenile-onset hyperuricemia.
|
21594610 |
2011 |
rs753397550
|
|
|
0.010 |
GeneticVariation |
BEFREE |
ZPBP2 p.T69I was at the non-conserved region and was predicted to be benign by in silico analysis, whereas GPATCH8 p.A979P was at a highly conserved region and was predicted to be deleterious, which made p.A979P a conceivable candidate for juvenile-onset hyperuricemia.
|
21594610 |
2011 |
rs1232898090
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Unadjusted and adjusted multiple logistic regressions showed that the odds ratios (OR) for hyperuricemia were not associated with Pro12Ala polymorphism in PPAR-γ2.
|
21968942 |
2012 |
rs1217691063
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Although the mechanism of the relationship between the C677T polymorphism and uric acid still remains unclear, these original articles showed that the MTHFR C677T polymorphism may be an independent risk factor for hyperuricemia.
|
22286863 |
2012 |
rs12979860
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Multivariate logistic regression analysis showed that age (OR 1.043, 95% CI 1.012-1.075, p=0.007), triglycerides (OR 1.005, 95% CI 1.000-1.010, p=0.04), hyperuricemia (OR 5.027, 95% CI 1.839-13.742, p=0.002), IL28B rs12979860 TT/TC (OR 0.219, 95% CI 0.101-0.472, p<0.001), and steatosis grade (OR 1.704, 95% CI 1.048-2.773, p=0.03) were independently linked to moderate-severe lobular inflammation.
|
22314430 |
2012 |